2012-10-05 16:57:08 - New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Global Markets Direct's, 'Respiratory Depression - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Respiratory Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Depression. Respiratory Depression - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated

disease.


Full Report Details at
- www.fastmr.com/prod/468427_respiratory_depression_pipeline_revie ..


Scope

* A snapshot of the global therapeutic scenario for Respiratory Depression.
* A review of the Respiratory Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Respiratory Depression pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Respiratory Depression.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Respiratory Depression pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Respiratory Depression Overview
Therapeutics Development
An Overview of Pipeline Products for Respiratory Depression
Respiratory Depression Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Respiratory Depression Therapeutics - Products under Development by Companies
Companies Involved in Respiratory Depression Therapeutics Development
Cortex Pharmaceuticals, Inc.
Galleon Pharmaceuticals
Sihuan Pharmaceutical Holdings Group Ltd.
Respiratory Depression - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CX-1796 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CX-1942 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CX-717 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nalmefene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GAL-054 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Respiratory Depression Therapeutics - Drug Profile Updates
Respiratory Depression - Product Development Milestones
Featured News & Press Releases
May 07, 2012: Galleon Reports Positive Results From Phase I Study Of GAL-021 For Treatment Of Respiratory Depression
Aug 24, 2011: Cortex Receives US Patent For Use Of Ampakine Molecules To Treat Respiratory Depression
Nov 04, 2009: Aeolus Pharmaceuticals' AEOL 10150 Protects Lungs Against Chlorine Gas Exposure In Animal Studies
Nov 03, 2008: Cortex's AMPAKINE Research In Opioid Makes Windhover's Top 10 List of Neuroscience Projects Available For Partnering
Oct 29, 2008: Discovery Labs Kl-4 Surfactant Data Presented At Two Key Medical Meetings
Oct 06, 2008: Cortex's AMPAKINE Compound, CX717, Achieves Primary Endpoints In Second Phase IIa Respiratory Depression Study
Aug 06, 2008: Cortex's AMPAKINE Molecule CX717 Reports Positive Effects In Opiate-Induced Respiratory Depression In Phase IIa Clinical Study
Jul 31, 2008: Cortex To Provide Top Line Data For CX717 Clinical Trial For The Prevention Of Opiate-Induced Respiratory Depression In Humans
Mar 07, 2008: Cortex Receives Approval From German Regulatory Authority To Proceed With Two Clinical Trials For AMPAKINE CX717 For The Acute Treatment Of Respiratory Depression
Feb 15, 2007: Health Canada Approves Significant New Medical Claims for COLD-fX
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Respiratory Depression, H2 2012
Products under Development for Respiratory Depression - Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468427&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.